Patent Assignment
Reel/Frame 050352/0339
Change of Name
Recorded: 2019-09-12
Pages: 7
Assignor
NLS-1 PHARMA AG
Executed: 2019-07-17
Assignee
NLS PHARMACEUTICS AG
ALTER POSTPLATZ 2, STANS, 6370, SWITZERLAND
Covered Properties
(3)
Mazindol Combination in the Treatment of Attention Deficit/Hyperactivity
A Mazindol Ir/Sr Multilayer Tablet and Its Use for the Treatment of Attention Deficit/Hyperactivity Disorder (Adhd)
Mazindol Combination in the Treatment of Attention-Deficit/Hyperactivity
Application:
16/507,424 →
Publication:
US 2019/0328714
Related Assignments
(4)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Feb 7, 2009
From: KONOFAL, ERIC
To: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
Reel/Frame 022221/0942 →
Assignment of Assignor's Interest
Nov 16, 2016
From: L'ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
To: NLS-1 PHARMA AG
Reel/Frame 040906/0825 →
Corrective Assignment to Correct the Assignee Address Previously Recorded at Reel: 040906 Frame: 0825. Assignor(S) Hereby Confirms the Assignment.
Jan 17, 2017
From: L'ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
To: NLS-1 PHARMA AG
Reel/Frame 041379/0310 →
Assignment of Assignor's Interest
Oct 5, 2018
From: ZWYER, ALEXANDER C.; AMSEL, LEWIS P.; SCHMITH, VIRGINIA; BRANTLEY, SCOTT
To: NLS-1 PHARMA AG
Reel/Frame 047083/0210 →